85-1400-48　EP1 Receptor, Mouse, Control Peptide 100ug　E3364

特徴

• Control peptide for E3364-10 (antiserum) and E3364-15 (affinity purified antibody).
• Prostanoids are the cyclooxygenase metabolites derived from C-20 unsaturated fatty acids (arachidonic acid). They include prostaglandin (PG) D2, PGE2, PGF2 alpha, PGI2, and thrombaxane (Tx) A2. The fatty acids precursors are released from the membrane phosphoplipids in response to various physiological and pathological stimuli by the action of phospholipase A2. They are converted to various prostanoids by the sequential actions of cyclooxygenases and the respective synthases. Prostaglandin PGE2 is one of the major prostaglandin produced during inflammation. A variety of PGE2-mediated effects on vascular smooth muscle tonus, glomerular cell function, renin release, and renal salt and water transport have been described. PGs also influence neuronal activity by modulating neurotransmitter release, sensitizing secretory fibers to noxious stimuli, or inducing fever and sleep. The actions of PGE2 are mediated by rhodopsin-type; G-protein coupled membrane receptors, termed E-prostanoid (EP) receptors or PTGERs. There are four subtypes of PGE receptors designated as EP1, EP2, EP3, and EP4. These receptors are encoded by different genes and expressed differently in each tissue. The intracellular signaling also differs among the receptor subtypes. In general, EP receptors display a protein topology typical of GPCR- 7 TM domain, an extracellular N-terminus, and a large intracellular C-terminus.
• EP1 (mouse/rat 405aa, human 402aa, chromosome 19p13.1; ~84% interspecies homology) expression is restricted to kidney (papillary collecting ducts), lung, and stomach (muscularis mucosae layer), spleen, skeletal muscle, testis, and uterus. EP1 has also been localized in neurons of the DRG. An alternatively spliced variant, a 366aa protein carrying a specific change if 49aa from the middle of TM VI to C-terminus, has also been described in rat uterus. The variant is also expressed in the kidney.
• Applications:Suitable for use in ELISA and Antibody Blocking. Not suitable for use in Western Blot due to low molecular weight. Other applications not tested.
• Recommended Dilution:Antibody Blocking: 5-10ug per 1ul E3364-10 (antiserum) or per 1ug E3364-15 (affinity purified antibody)
• ELISA: Coat ELISA plates at 1ug/ml Control Peptide
• Optimal dilution determined by the researcher.
• Storage and Stability:May be stored at 4°C for short-term only. For long-term storage, store at -20°C. Aliquots are stable for at least 6 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.